Mycardis, tablets 40 mg 28 pcs

– arterial hypertension;
– reduction of cardiovascular morbidity and mortality in patients aged 55 years and older with a high risk of cardiovascular disease.

Indications

— arterial hypertension;
– reduction of cardiovascular morbidity and mortality in patients aged 55 years and older with a high risk of cardiovascular disease.

Pharmacological effect

Clinical and pharmacological group:

Special instructions

In some patients, due to suppression of the RAAS, especially when using a combination of drugs acting on this system, renal function is impaired (including acute renal failure). Therefore, therapy accompanied by such a double blockade of the RAAS (for example, when adding ACE inhibitors or the direct renin inhibitor aliskiren to angiotensin II receptor antagonist blockers) should be carried out strictly individually and with careful monitoring of renal function (including periodic monitoring of serum potassium and creatinine concentrations).

Active ingredient

Telmisartan

Composition

Tablets are white or almost white, oblong, with “52H” engraved on one side and the company symbol on the other side.
1 tab.

Contraindications

— obstructive diseases of the biliary tract;
– severe liver dysfunction (class C on the Child-Pugh scale);
– simultaneous use with aliskiren in patients with diabetes mellitus or renal failure (GFR <60 ml/min/1.73 m2);
– fructose intolerance, glucose/galactose malabsorption syndrome or sucrase/isomaltase deficiency;
– age under 18 years (efficacy and safety have not been established);
— pregnancy;
– period of breastfeeding;
– hypersensitivity to the active substance or auxiliary components of the drug.
With caution
– bilateral renal artery stenosis or stenosis of the artery of a single kidney;
– liver and/or kidney dysfunction;
– decrease in blood volume due to previous diuretic therapy, restriction of salt intake, diarrhea or vomiting;
— hyponatremia;
— hyperkalemia;
— conditions after kidney transplantation (no experience of use);
— chronic heart failure;
— stenosis of the aortic and mitral valve;
— idiopathic hypertrophic subaortic stenosis;
— primary aldosteronism (efficacy and safety have not been established).

Side Effects

The observed incidence of side effects did not correlate with the gender, age or race of the patients.

Interaction

Telmisartan may increase the hypotensive effect of other antihypertensive agents. No other interactions of clinical significance have been identified.

Overdose

No cases of overdose have been identified.

Storage conditions

The drug should be stored out of the reach of children, protected from moisture at a temperature not exceeding 30°C.

Shelf life

4 years.

Manufacturer

Boehringer Ingelheim Pharma GmbH & Co.KG, Germany